Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 548

1.

Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.

Martin JL, de Silva HC, Lin MZ, Scott CD, Baxter RC.

Mol Cancer Ther. 2014 Feb;13(2):316-28. doi: 10.1158/1535-7163.MCT-13-0367. Epub 2013 Dec 12.

2.

Potentiation of growth factor signaling by insulin-like growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activity.

Martin JL, Lin MZ, McGowan EM, Baxter RC.

J Biol Chem. 2009 Sep 18;284(38):25542-52. doi: 10.1074/jbc.M109.007120. Epub 2009 Jul 25.

3.

MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.

Kim YJ, Choi JS, Seo J, Song JY, Lee SE, Kwon MJ, Kwon MJ, Kundu J, Jung K, Oh E, Shin YK, Choi YL.

Int J Cancer. 2014 May 15;134(10):2424-36. Erratum in: Int J Cancer. 2014 Oct 1;135(7):E6.

4.

Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer.

Marzec KA, Baxter RC, Martin JL.

Biomed Res Int. 2015;2015:638526. doi: 10.1155/2015/638526. Epub 2015 Jun 28. Review.

5.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

6.
7.

The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents.

Lin MZ, Marzec KA, Martin JL, Baxter RC.

Oncogene. 2014 Jan 2;33(1):85-96. doi: 10.1038/onc.2012.538. Epub 2012 Nov 26.

PMID:
23178489
8.

Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR.

Wang YL, Overstreet AM, Chen MS, Wang J, Zhao HJ, Ho PC, Smith M, Wang SC.

Oncotarget. 2015 May 10;6(13):11150-61.

9.

Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion.

Shida D, Fang X, Kordula T, Takabe K, Lépine S, Alvarez SE, Milstien S, Spiegel S.

Cancer Res. 2008 Aug 15;68(16):6569-77. doi: 10.1158/0008-5472.CAN-08-0411.

10.
11.

The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.

Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A, Van Brocklyn JR.

J Neurooncol. 2011 May;102(3):353-66. doi: 10.1007/s11060-010-0345-z. Epub 2010 Oct 12.

12.

Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.

Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL.

Mol Cancer Ther. 2014 May;13(5):1356-68. doi: 10.1158/1535-7163.MCT-13-1021. Epub 2014 Mar 14.

13.

IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin.

McIntosh J, Dennison G, Holly JM, Jarrett C, Frankow A, Foulstone EJ, Winters ZE, Perks CM.

J Biol Chem. 2010 Dec 10;285(50):38788-800. doi: 10.1074/jbc.M110.177311. Epub 2010 Sep 17.

14.

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA.

J Clin Invest. 2008 Jul;118(7):2609-19. doi: 10.1172/JCI34588.

15.

A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.

Zhan Y, Zhang Y, Liu C, Zhang J, Smith WW, Wang N, Chen Y, Zheng L, He L.

Cancer Prev Res (Phila). 2012 Jun;5(6):864-73. doi: 10.1158/1940-6207.CAPR-11-0575. Epub 2012 Apr 11.

16.

Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.

Bessette DC, Tilch E, Seidens T, Quinn MC, Wiegmans AP, Shi W, Cocciardi S, McCart-Reed A, Saunus JM, Simpson PT, Grimmond SM, Lakhani SR, Khanna KK, Waddell N, Al-Ejeh F, Chenevix-Trench G.

PLoS One. 2015 May 13;10(5):e0125232. doi: 10.1371/journal.pone.0125232. eCollection 2015.

17.

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.

Corkery B, Crown J, Clynes M, O'Donovan N.

Ann Oncol. 2009 May;20(5):862-7. doi: 10.1093/annonc/mdn710. Epub 2009 Jan 15.

PMID:
19150933
18.
19.

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.

Shapira I, Lee A, Vora R, Budman DR.

Crit Rev Oncol Hematol. 2013 Nov;88(2):284-92. doi: 10.1016/j.critrevonc.2013.05.003. Epub 2013 Jun 5. Review.

PMID:
23755891
20.

Supplemental Content

Support Center